Bullish Case: Known: Berkshire all-cash acquisition anchors TMHC near ~$72.50; TMHC ~$71.6 with calls >> puts (96% call volume) and TMHC currently in backwardation. The TMHC return surface’s highest-likelihood band clusters around roughly +8% to +20% over ~1y holds, and mean reversion suggests drift back toward the deal floor. SPY’s IV surface shows near-term risk priced much higher than far-dated (front-days ~30–40 vol vs later ~10–15), so “calm” days can compress spreads. My earlier May downside calls calibrated too high; deal repricing looks stronger.

Bearish Case: Known upside can still unwind: deal spread can widen on antitrust/closing-delay risk, even if long-run housing is fine. The TMHC return-surface tail has comparatively less likelihood below ~-10% but it’s non-trivial, and heavy put activity/backwardation keeps downside hedging relevant. SPY IV’s skew toward downside strikes implies macro risk premium persists near the front end. If rates or order momentum worsen, TMHC could break below the deal floor toward ~$62–66. My prior “>20% drawdown” bearish scenario didn’t materialize, so the falsifiable target is more like -10% to -15% than -25%.

Potential Outcomes:

1. 45%: Deal spread narrows → TMHC $72.5–$76 (watch filings/approval clarity).
2. 25%: Mean-reverting chop $68–$74 as IV normalizes.
3. 15%: Antitrust/close-delay widens spread → $62–$66.
4. 10%: Rate shock + weak housing → $56–$62.
5. 5%: Policy/housing surprise → $78–$82.

Oracle: if price tracks the deal floor, call-spread bias tends to fit; if spread widens, put-protection tends to matter more.

June 04, 2026